Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

被引:5
|
作者
Onishi, Sachiyo [1 ]
Tajika, Masahiro [1 ]
Tanaka, Tsutomu [1 ]
Yamada, Keisaku [1 ]
Kamiya, Tomoyasu [1 ]
Abe, Tetsuya [2 ]
Higaki, Eiji [2 ]
Fujieda, Hironori [2 ]
Nagao, Takuya [2 ]
Inaba, Yoshitaka [3 ]
Muro, Kei [4 ]
Shimizu, Masahito [5 ]
Niwa, Yasumasa [1 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Endoscopy, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[2] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[3] Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[4] Aichi Canc Ctr Hosp, Dept Clin Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[5] Gifu Univ, Grad Sch Med, Dept Gastroenterol Internal Med, 1-1 Yanagido, Gifu 5011194, Japan
关键词
esophageal squamous cell carcinoma; neoadjuvant chemotherapy; sarcopenia; SKELETAL-MUSCLE MASS; PULMONARY COMPLICATIONS; PSOAS MUSCLE; SARCOPENIA; CANCER; OUTCOMES; PREDICTOR; NUTRITION; MORTALITY; IMPACT;
D O I
10.3390/jcm11030508
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effects of changes in body composition during neoadjuvant chemotherapy (NAC) on perioperative complications and prognosis are unknown in patients with esophageal squamous cell carcinoma (ESCC). A total of 175 patients who underwent surgery for ESCC in our hospital between 2016 and 2019 were examined. The psoas muscle index (PMI) was calculated from the total psoas muscle area, and the visceral fat mass (VFM) at the umbilical level was measured. We defined body composition change (BCC) group as those with increased VFM of >= 3% and decreased PMI of >= 3% during NAC. Sarcopenia (S) was defined as PMI < 5.89 (male) and <4.06 (female). Nutritional assessment using the Subjective Global Assessment tool was performed upon admission. The percentages of BCC group, pre-NAC S, and post-NAC S was 32.5%, 79.4%, and 80.0%, respectively. BCC group had significantly more postoperative complications (p < 0.01) and longer hospital stays (p = 0.03) than groups pre-NAC S and post-NAC S. Overall survival (OS) analysis using the Cox hazard model showed that stage III (p < 0.01) and post-NAC S (p = 0.03) were poor prognostic factors. Changes in body composition during NAC affected perioperative complications and prognosis of patients with ESCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Impact of Body Composition on Clinical Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Plus Chemotherapy
    Zhao, Yuan
    Xia, Mingxin
    Dang, Yan
    Li, Yifan
    Zhao, Xiaoying
    Kang, Ningning
    Zuo, Jianhui
    Zhang, Renquan
    ANNALI ITALIANI DI CHIRURGIA, 2024, 95 (03) : 284 - 293
  • [2] Relationships among body composition, muscle strength, and sarcopenia in esophageal squamous cell carcinoma patients
    Sugawara, Kotaro
    Yamashita, Hiroharu
    Okumura, Yasuhiro
    Yagi, Koichi
    Yoshimura, Shuntaro
    Kawasaki, Koichiro
    Tanabe, Asami
    Aikou, Susumu
    Seto, Yasuyuki
    SUPPORTIVE CARE IN CANCER, 2020, 28 (06) : 2797 - 2803
  • [3] Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy
    Torigoe, Rikuya
    Oshikiri, Taro
    Goto, Hironobu
    Koterazawa, Yasuhumi
    Sawada, Ryuichiro
    Ikeda, Taro
    Harada, Hitoshi
    Urakawa, Naoki
    Hasegawa, Hiroshi
    Kanaji, Shingo
    Yamashita, Kimihiro
    Matsuda, Takeru
    Kakeji, Yoshihiro
    ANTICANCER RESEARCH, 2024, 44 (12) : 5485 - 5493
  • [4] Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma
    Sugawara, Kotaro
    Fukuda, Takashi
    Murakami, Chiaki
    Oka, Daiji
    Yoshii, Takako
    Amori, Gulanbar
    Ishibashi, Kumiko
    Kobayashi, Yasuhito
    Hara, Hiroki
    Kanda, Hiroaki
    Motoi, Noriko
    CANCER SCIENCE, 2024, 115 (08) : 2819 - 2830
  • [5] Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma
    Nakashima, Yuichiro
    Saeki, Hiroshi
    Hu, Qingjiang
    Tsuda, Yasuo
    Hisamatsu, Yuichi
    Ando, Koji
    Oki, Eiji
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2018, 38 (12) : 6809 - 6814
  • [6] Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Loc, Nguyen Vo Vinh
    Vuong, Nguyen Lam
    Trung, Lam Viet
    Trung, Tran Thien
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (04) : 1240 - 1251
  • [7] Body composition change during neoadjuvant chemotherapy for breast cancer
    Jang, Min Kyeong
    Park, Seho
    Park, Chang
    Doorenbos, Ardith Z.
    Go, Jieon
    Kim, Sue
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Sun, Hai-Bo
    Yan, Sen
    Liu, Xian-Ben
    Xing, Wen-Qun
    Chen, Pei-Nan
    Liu, Shi-Lei
    Li, Peng
    Ma, Ya-Xing
    Lerut, Toni
    Daoud, Ahmed
    Jiang, Duo
    Sun, Hai-Bo
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (02) : 1200 - 1201
  • [9] Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
    Ma, Shaohua
    Yan, Tiansheng
    Liu, Dandan
    Wang, Keyi
    Wang, Jingdi
    Song, Jintao
    Wang, Tong
    He, Wei
    Bai, Jie
    Jin, Liang
    Chen, Xiaoxin
    THORACIC CANCER, 2018, 9 (02) : 310 - 315
  • [10] Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma
    Nagai, Yohei
    Yoshida, Naoya
    Baba, Yoshifumi
    Harada, Kazuto
    Imai, Katsunori
    Iwatsuki, Masaaki
    Karashima, Ryuichi
    Koga, Yuki
    Nomoto, Daichi
    Okadome, Kazuo
    Ishimoto, Takatsugu
    Imamura, Yu
    Watanabe, Masayuki
    Baba, Hideo
    DIGESTIVE ENDOSCOPY, 2020, 32 (01) : 39 - 48